US FDA Reorganization Advocates Seek Senate Boost For Disease-Oriented Structure
This article was originally published in Clinica
Executive Summary
A proposal to reorganize the US FDA's centers from a product-based structure to one oriented by therapeutic area could gain more traction with the Senate's forthcoming draft of its medical innovation legislation.